Sernova (TSE:SVA) Price Target Lowered to C$2.50 at Ventum Financial

Sernova (TSE:SVA) had its target price lowered by Ventum Financial from C$3.00 to C$2.50 in a report issued on Friday, BayStreet.CA reports. Ventum Financial currently has a buy rating on the stock.

Separately, Leede Financial cut their target price on shares of Sernova from C$3.00 to C$1.50 and set a speculative buy rating for the company in a research note on Friday.

Sernova Trading Down 5.8 %

Shares of Sernova stock opened at C$0.25 on Friday. The business has a fifty day simple moving average of C$0.27 and a 200-day simple moving average of C$0.37. Sernova has a fifty-two week low of C$0.20 and a fifty-two week high of C$0.83. The firm has a market cap of C$79.48 million, a price-to-earnings ratio of -1.88 and a beta of 1.38. The company has a quick ratio of 18.11, a current ratio of 0.62 and a debt-to-equity ratio of 16.55.

Sernova (TSE:SVA) last issued its quarterly earnings results on Friday, June 14th. The company reported C($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of C($0.03). On average, equities analysts forecast that Sernova will post -0.08 EPS for the current fiscal year.

Insider Activity

In related news, Director Steven Sangha sold 930,000 shares of Sernova stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of C$0.24, for a total value of C$223,200.00. Insiders purchased a total of 359,600 shares of company stock valued at $92,771 over the last three months. Insiders own 12.98% of the company’s stock.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.